Microtiter cell-based assay for detection of agents that alter cellular levels of Her2 and EGFR

Chemistry and Biology

Volumn 10, Issue 7, 2003, Pages 629-634

  Huezo, Henri ^a   Vilenchik, Maria ^a   Rosen, Neal ^a   Chiosis, Gabriela ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0043132154     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(03)00144-3     Document Type: Article

References (20)

1. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
2. Gullick W.J. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br. Med. Bull. 47:1991;87-98.
3. Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer. 37:2001;S9-15.
4. Guy C.T., Webster M.A., Schaller M., Parsons T.J., Cardiff R.D., Muller W.J. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA. 89:1992;10578-10582.
5. Muller W.J., Sinn E., Pattengale P.K., Wallace R., Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell. 54:1988;105-115.
6. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2:2001;127-137.
7. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 19:2000;6550-6565.
8. Citri A., Alroy I., Lavi S., Rubin C., Xu W., Grammatikakis N., Patterson C., Neckers L., Fry D.W., Yarden Y. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases. implications for cancer therapy EMBO J. 21:2002;2407-2417.
9. Fry D.W., Bridges A.J., Denny W.A., Doherty A., Greis K.D., Hicks J.L., Hook K.E., Keller P.R., Leopold W.R., Loo J.A.et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. USA. 95:1998;12022-12027.
10. Neckers L., Schulte T.W., Mimnaugh E. Geldanamycin as a potential anti-cancer agent. its molecular target and biochemical activity Invest. New Drugs. 17:1999;361-373.
11. Schulte T.W., Neckers L.M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to Hsp90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol. 42:1998;273-279.
12. Schulte T.W., Akinaga S., Soga S., Sullivan W., Stensgard B., Toft D., Neckers L.M. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones. 2:1998;100-108.
13. Chiosis G., Timaul M.N., Lucas B., Munster M.N., Zheng F.F., Sepp-Lorenzino L., Rosen N. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 8:2001;289-299.
14. Chiosis G., Huezo H., Lucas B., Rosen N. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg. Med. Chem. 10:2002;3555-3564.
15. Marcu M., Schulte T.W., Neckers L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J. Natl. Cancer Inst. 92:2000;242-248.
16. Yu X., Guo Z.S., Marcu M.G., Neckers L., Nguyen D.M., Chen G.A., Schrump D.S. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl. Cancer Inst. 94:2002;504-513.
17. Stockwell B.R., Haggarty S.J., Schreiber S.L. High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications. Chem. Biol. 6:1999;71-83.
18. Zhang J.-H., Chung T.D.Y., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4:1999;67-73.
19. Sakagami M., Morrison P., Welch W.J. Benzoquinoid ansamycins (herbimycin A and geldanamycin) interfere with the maturation of growth factor receptor tyrosine kinases. Cell Stress Chaperones. 4:1999;19-28.
20. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 50:1985;76-85.